Recent advances in understanding haemochromatosis: A transition state

Journal of Medical Genetics

Volumn 41, Issue 10, 2004, Pages 721-730

  Robson, Kathryn J H ^a   Merryweather Clarke, Alison T ^a   Cadet, E ^b   Viprakasit, V ^a,c   Zaahl, M G ^d   Pointon, J J ^e   Weatherall, D J ^a   Rochette, J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c MAHIDOL UNIVERSITY   (Thailand)

^d STELLENBOSCH UNIVERSITY   (South Africa)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOJUVELIN; HEPCIDIN; IRON; PEPTIDE HORMONE; UNCLASSIFIED DRUG;

DISEASE CLASSIFICATION; DISEASE SEVERITY; GENE; GENE MUTATION; GENETIC DISORDER; HAMP GENE; HEMOCHROMATOSIS; HJV GENE; HOST RESISTANCE; HUMAN; INFECTION; INHERITANCE; INTESTINE ABSORPTION; IRON ABSORPTION; IRON METABOLISM; JUVENILE HEMOCHROMATOSIS; MASS SCREENING; NONHUMAN; POPULATION GENETICS; PRIORITY JOURNAL; REVIEW;

GENETIC SCREENING; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INFECTION; IRON OVERLOAD; MEMBRANE PROTEINS;

EID: 6344237322     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.020644     Document Type: Review

References (175)

1. Sheldon JH. Haemochromatosis. Oxford: Oxford University Press, 1935.
2. Saddi R, Feingold J. Idiopathic haemochromatosis: an autosomal recessive disease. Clin Genet 1974;5:234-41.
3. Simon M, Baurel M, Genetet B, Fauchet R. Idiopathic hemochromatosis- demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977;297:1017-21.
4. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo Jr R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class Mike gene is mutated in patients with hereditary haemochromatosis. Nat Genet J 1996;13:399-408.
5. Jouanolle AM, Gandon G, Blayau M, Campion ML, Yaouanq J, Mosser J, Fergelot P, Chauvel B, Bauric P, Carn G, Andrieux N, Le Gall J-Y, David V. Haemochromatosis and HLA-H. Nat Gene 1996;14:251-2.
6. Jazwinska EC, Cullen, LM, Busfield F, Pyper WR, Webb SI, Powell LP, Morris CP, Walsh TP. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-51.
7. Worwood M, Shearman JD, Wallace DF, Dooley JS, Merryweather-Clarke AT, Pointan JJ, Rosenberg WMC, Bowen DJ, Burnett AK, Jackson HA, Lawless S, Raha-Chowdhury R, Partridge J, Williams R, Bamford A, Walker AP, Robsom KJH: A simple genetic test identifies 90% of UK patients with haemochromatosis. Gut 1997;41:841-4.
8. Merryweather-Clarke AT, Pointon JJ, Jouanolle AM, Rochette J, Robson KJH. Geography of HFE C282Y and H63D mutations. Genet Test 2000;4:183-98.
9. Merryweather-Clarke AT, Pointan JJ, Shearman JD, Robson KJH. Global prevalence: of putative haembchromatosis mutations. J Med Genet 1997;34:275-8
10. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000;4:151-61
11. Steiner M, Ocran K, Genshel J, Meier P, Gerl H, Ventz M, Schneider M-L, Büttner C, Wadoska K, Kerner W, Shuff-Werner P, Lochs H, Schmidt H. A homozygous HFE gene splice mutation (IVS5+1G/A in a hereditary hemochromatosis patient of Vietnamese origin. Gastroenterology 2002;122:789-95
12. Levy JE, Montross LK, Cohen DE, Flemming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999;94:9-11
13. Bastin JM, Jones M, O'Callaghan CA, Shimanski L, Mason DY, Townsend ARM. Kupffer cell staining by an HFE-specific monoclonal antibody implications for hereditary haemochromatosis. Br J Haematol 1998;103:931-41
14. Parkkila S. Waheed A, Britton RS, Feder JN, Tsuchihashi Z, Shatzman RC, Bacon BR, Sly WS. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci U S A 1997;94:2534-9
15. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY, Tomatsu S, Fleming RE, Sly WS. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci U S A 1997;94:13198-202
16. Parkkila S, Waheed A, Britton RS, Zhou XY, Fleming RE, Tomatsu S, Bacon BR, Sly WS. Cell surface expression of HFE protein in epithelial cells, macrophages, and monocytes. Haematologica 2000;85:340-5.
17. Griffiths WJ, Cox TM. Co-localization of the mammalian hemochromatasis gene product (HFE) and a newly identified transferrin receptor (TfR2) in intestinal tissue and cells. J Histochem Cytochem 2003;51(5):613-24.
18. Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicates that HFE is expressed predominantly in hepatocytes. Blood 2004;103:1509-14.
19. Camaschella C, Roetto A, Cali A, De Gabbi M, Garozzo G, Carella M, Majorano N, Totoro A, Gasparini P. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000;25:14-5.
20. Montosi G, Donovan A, Totoro A, Garuti C, Pignatti E, Cassaneli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;108:619-23.
21. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JWF, Breuning MH, Snijders PJLM, Rutten WPF, Sandkuijl LA, Oostra BA, van Duijn CM, Heutink P. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001;28:213-4.
22. Roetto A, Papanikoloau G, Politou M, Alberti F, Girelli D, Christokis J, Loukopoulos D, Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile haemochromatosis. Nat Genet 2003;33:21-2.
23. Papanikolaou G, Samuels ME, Ludwig EH, MacDonald MLE, Franchini PL, Dubé M-P, Andres L, MacFarlane J, Sakellaropoulos N, Politou M, Nemeth E, Thompson KJ, Risler JK, Zaborowska C, Babakaiff R, Radomski CC, Pape TD, Dovidas O, Christokis J, Brissot P, Lockitch G, Ganz T, Hayden MR, Goldberg YP. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 2004;36:77-82.
24. Kelly AL, Lunt PW, Rodrigues F, Berry PJ, Flynn DM, McKiernan PJ, Kelly DA, Mieli-Vergani G, Cox TM. Classification and genetic features of neonatol haemochromatosis: a study of 27 affected pedigrees and molecular analysis of genes implicated in iron metabolism. J Med Genet 2001;38:599-610.
25. Camaschella C. Juvenile hemochromatosis. In: Powell L, ed. Hereditary diseases of the liver, Vol 12. London: Baillière Tindall, 1998:227-35.
26. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276:7896-910.
27. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J Biol Chem 2002;277:37597-603.
28. Roetto A, Daraio F, Porporato P, Caruso R, Cox TM, Cazzola M, Gasparini P, Piperno A, Camaschella C. Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood 2004;103:2407-9.
29. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-81.
30. Nicolas G, Chauvet C, Viatte L, Dona JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia. J Clin Invest 2002;110:1037-44.
31. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001;998:8780-5.
32. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Laréal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276:7811-9.
33. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3.
34. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramanian VN, Powell LW, GJA, Ramm GA. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostosis. Lancet 2003;361:669-73.
35. Kulaksiz H, Gehrke SG, Janetzko A, Rost D, Bruckner T, Kallinowski B, Stremmel W. Pro hepcidin: expression and cell specific localization in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia. Gut 2004;53:735-43.
36. Roetto A, Totaro A, Cazzola M, Ciciliano M, Basia S, D'Ascola G, Carella M, Zelante. L, Kelly AL, Cox TM, Gasparini P, Camaschella C. The juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999;64:1388-93.
37. Roetto A, Totaro A, Piperno A, Piga A, Longo F, Garozzo G, Cali A, De Gobbi M, Gasparini P, Camaschella C. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001;97:2555-60.
38. Mattman A, Huntsman D, Lockitch G, Langlois S, Buskard N, Ralston D, Butterfield Y, Rodrigues P, Jones S, Porto G, Marra M, De Sousa M, Vatcher G. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 2002;100:1075-7.
39. Hofmann WK, Tong XJ, Ajioka RS, Kushner JP, Koeffler HP. Mutation analysis of transferrin-receptor 2 in patients with atypical hemochromatosis. Blood 2002;100:1099-100.
40. Girelli D, Bozzini C, Roetto A, Alberti F, Daroio F, Colombori R, Olivieri O, Corrocher R, Camaschella C. Clinical and pathologic findings in hemochromatosis type 3 due to a novel-mutation in transferrin receptor 2 gene. Gastroenterology 2002;22:1295-302.
41. Roetto A, Daraio F, Alberti F, Porporato P, Cali A, De Gabbi M, Camaschella C. Hemochromatosis due to mutations in transferrin receptor 2. Blood Cell Mol Dis 2002;29:465-70.
42. Biasiotto G, Belloli S, Ruggeri G, Zanella I, Gerardi G, Corrado M, Gabbi E, Albertini A, Arosio P. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin Chem 2003;49:1981-8.
43. Hattori A, Wakusawa S, Hayashi H, Harashima A, Sanae F, Kawanaka M, Yamada G, Yano M, Yoshioka K. AVAQ 594-597 deletion of the TfR2 gene in a Japanese family with hemochromatosis. Hepatol Res 2003;26:154-6.
44. Lanzara C, Roetto A, Daraio F, Rivard SR, Ficarella R, Simard H, Cox TM, Cazzola M, Piperno A, Gimenez-Roqueplo A-P, Grammatico P, Volinia S, Gasparini P, Camaschella C. The spectrum of hemojuvelin gene mutation in 1q-linked juvenile hemochromatosis. Blood 2004;103:4317-21.
45. Lee PL, Beutler E, Rao SV, Barton JC. Genetic abnormalities and juvenile hemochromatosis: mutations of the HJV gene encoding hemojuvelin. Blood 2004;103:4669-71.
46. Huang FW, Rubio-Aliaga I, Kushner JP, Andrews NC, Fleming MD. Identification of a novel mutation (C321X) in HJV. Blood 2004 (May 11; epub ahead of print).
47. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285(5430):1028-32.
48. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, Bacon BR, Sly WS. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and hereditary hemochromatasis. Proc Natl Acad Sci U S A 2000;97:2214-9.
49. Hannuksela J, Parkkila S, Waheed A, Britton RS, Fleming RE, Bacon BR, Sly WS. Human platelets express hemochromatosis protein (HFE) and transferrin receptor 2. Eur J Haematol 2003;70:201-6.
50. West AP Jr, Bennett MJ, Sellers VM, Andrews NC, Enns CA, Bjorkman PJ. Comparison of the interactions of transferrin receptor and transferrin receptor 2 with transferrin and the hereditary hemochromatasis protein HFE. J Biol Chem 2000;275(49):38135-8.
51. Pietrangelo A, Montasi G, Totaro A, Goruti C, Conte D, Cassanelli S, Fraquelli M, Sardini C, Vasta F, Gasparini P. Hereditary hemochromatasis in adults without pathogenic mutations in the hemochromatasis gene. N Engl J Med 1999;341:725-32.
52. Eason R, Adams P, Astan C, Searle J. Familial iron overload with possible autasomal dominant inheritance. Aust N Z J Med 1990;20:226-30.
53. Arden KE, Wallace DF, Dixon JL, Summerville L, Searle JW, Anderson GJ, Ramm GA, Powell LW, Subramaniam VN. A novel mutation in ferroportin 1 is associated with haemochromatosis in a Solomon Islands patient. Gut 2003;52:1215-7.
54. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (SLC11A3) mutations. Blood 2003;102:1904-10.
55. Jouanolle AM, Douabin-Gicquel V, Halimi C, Loreal O, Fergelot P, Delacour T, de Lajarte-Thirouard AS, Turlin B, Le Gall JY, Cadet E, Rochelte J, David V, Brissot P. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J Hepatol 2003;39:286-9.
56. Rivard SR, Lanzara C, Grimard D, Carella M, Simard H, Ficarella R, Simard R, D'Adamo AP, De Braekeleer M, Gasporini P. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica 2003;88:824-6.
57. Gordeuk VR, Caleffi A, Corradini E, Ferrara F, Jones RA, Castro O, Onyekwere O, Kittles R, Pignatti E, Montosi G, Garuti C, Gangaidzo IT, Gomo ZA, Movo VM, Rouault TA, MacPhail P, Pietrangelo A. Iron overload in Africans and African-Americans and a common mutation in the SLC40A1 (ferroportin 1) gene. Blood Cell Mol Dis 2003;31:299-304.
58. Beutler E, Barton JC, Felitti VJ, Gelbort T, West C, Lee PL, Waalen J, Vulpe C. Ferroportin 1 (SLC40A1) variant associated with iron overload in African-Americans. Blood Cell Mol Dis 2003;31:305-9.
59. Devalia V, Carter K, Walker AP, Perkins SJ, Worwood M, May A, Dooley JS. Autosomal dominant reticulo-endothelial iron overload associated with a three base poir deletion in the ferroportin 1 gene (SLC11A3). Blood 2002;100:695-7.
60. Roetto A, Merryweather-Clarke AT, Daraio R, Livesey K, Pointan JJ, Barbietola G, Piga A, Mackie PH, Robson KJH, Camaschella C. A valine deletion in ferroportin 1: a common mutation in hemochromatosis type 4? Blood 2002;100:733-4.
61. Wallace DF, Pedersen P, Dixon JL, Stephenson P, Searle JW, Powell LW, Subramaniam VN. Novel mutation in ferroportin 1 is associated with autasomal dominant hemochromatosis. Blood 2002;100:692-4.
62. Cazzola M, Cremonesi L, Papoioannou M, Soriani N, Kioumi A, Charalambidou A, Paroni R, Romtsou K, Levi S, Ferrari M, Arosio P, Christakis J. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferropartin gene (SLC11A3). Br J Haematol 2002;119:539-46.
63. Danovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palls J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776-81.
64. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzeneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG 1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309.
65. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-12.
66. Fleming RE, Sly WS. Ferroportin mutation in autasomal dominant hemochromatasis: loss of function, gain in understanding. J Clin Invest 2001;108:521-2.
67. Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cell Mol Dis 2003;30:288-97.
68. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role far ceruloplosmin in cellular iron efflux. Proc Natl Acad Sci U S A 1999;96:10812-7.
69. Vulpe CD, Kuo YM, Murphy TL, Cowley L, Askwith C, Libina N, Gitschier J, Andersen GJ. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat Genet 1999;21:195-9.
70. Mok H, Jelinek J, Pai S, Cattanach BM, Prchal JT, Youssoufian H, Schumacher A. Disruption of ferroportin 1 regulation causes dynamic alterations in iron homeostasis and erythropoiesis in polycythaemia mice. Development 2004;131(8):1859-68.
71. Townsend ARM, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet 2002;359:786-90.
72. Fleming RE, Sly WS. Mechanisms of iron accumulation in hereditary hemochromatosis. Annu Rev Physiol 2002;64:663-80.
73. Chorney MJ, Yoshida Y, Meyer PN, Yoshida M, Gerhard GS. The enigmatic role of the hemochromatasis protein (HFE) in iron absorption. Trend Mol Med 2003;9:118-25.
74. Kato J, Fujikawa K, Kanda M, Fukuda N, Sasaki K, Takayama T, Kobune M, Takada K, Takimota R, Hamada H, Ikeda T, Niitsu Y. A mutation, in the iron-responsive element of H ferritin mRNA, causing autasomal dominant iron overload. Am J Hum Genet 2001;69:191-7.
75. Beaumont C, Leneuve P, Devaux I, Scoazec JY, Berthier M, Loiseau MN, Grandchamp B, Banneau D. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. Nat Genet 1995;11:444-6.
76. Martin ME, Fargion S, Brissot P, Pellat B, Beaumont C. A point mutation in the bulge of the iron-responsive element of the L ferritin gene in two families with the hereditary hyperferritinemia-cataract syndrome. Blood 1998;91:319-23.
77. Ciciliano M, Zecchina G, Roetto A, Basio S, Infelise V, De Stefani S, Mazza U, Camaschella C. Hyperferritinemia-cataract syndrome: three recurrent mutations in the IRE of L-ferritin in Italian families. Haematologica 1999;84:489-92.
78. McLeod JL, Craig J, Gumley S, Roberts S, Kirkland MA. Mutation spectrum in Australian pedigrees with hereditary hyperferritinaemia-cataract syndrome reveals novel and de novo mutations. Br J Haematol 2002;118(4):1179-82.
79. Cazzola M. Hereditary hyperferritinaemia/cataract syndrome. Best Pract Res Clin Haematol 2002;15(2):385-98.
80. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995;92:2539-43.
81. Bosio S, De Gobbi M, Roetto A, Zecchina G, Leonardo E, Rizzetto M, Lucetti C, Petrozzi L, Bonuccelli U, Camaschella C. Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 2002;100:2246-8.
82. Gitlin JD. Aceruloplasminemia. Pediatr Res 1998;44:271-6.
83. Miyajima H, Takahashi Y, Kono S. Aceruloplasminemia, an inherited disorder of iron metabolism. Biometals 2003;16:205-13.
84. Merryweather-Clarke AT, Worwood M, Parkinson L, Mattock C, Pointon JJ, Shearman JD, Robson KJH. The effect of HFE mutations on serum ferritin and transferrin saturation in the Jersey population. Br J Haematol 1998;101:369-73.
85. Jackson HA, Carter K, Darke C, Guttridge MG, Ravine D, Hutton RD, Napier JA, Worwood M. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001;114:474-84.
86. Deugnier Y, Jouanolle A-M, Chaperon J, Moirand R, Pithois C, Meyer J-F, Poucnard M, Lofraise B, Brigand A, Caserio-Schoenemann C, Adams P, Le-Gall J-Y, David V. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatasis. A study of 9396 French people. Br J Haematol 2002;118:1170-8.
87. Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A 1983;80:2258-62.
88. Robson KJH, Merryweather-Clarke AT, Pointon JJ, Shearman JD, Halsall DJ, Kelly A, Cox TM, Rosenberg WM, Howell M, Eccles D, Patch C, Fowler AV, Wallace DF, Camaschella C, Roetto A, Zecchina G, De Gobbi M, Gasporini P, Cadet E, Vandwalle JL, Capron D, Rochette J, Barot N, Demangel C, Dery R, Vinel JP, Pascal JP, Coppin H, Roth M-P. Diagnosis and management of haemochromatosis since the discovery of the HFE gene: a Europeon experience. Br J Haematol 2000;108:31-9.
89. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbort T. Penetrance of 845G->A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
90. Beutler E, Felitti V, Koziol JA, Gelbort T. Clinical haemochromatosis in HFE mutation carriers. Lancet 2002;360:411-2.
91. Cox T, Rochette J, Camaschella C, Walker A, Robson K. Clinical haemochromatosis in HFE mutotion carriers. Lancet 2002;360:412.
92. Alien KJ, Warner B, Delatycki MB. Clinical haemochromatosis in HFE mutotion carriers. Lancet 2002;360:412-3.
93. McCune A, Worwood M. Penetrance in hereditary hemochromatosis. Blood 2003;102:2696; author reply 2696-7.
94. Cazzola M. Genetic disorders of iron overload and the novel "ferroportin disease". Haematologica 2003;88:721-4.
95. Pietrangelo A. The ferroportin disease. Blood Cell Mol Dis 2004;32:21-9.
96. Barton JC, Bertoli LF, Rothenberg BE. Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 2000;135:96-104.
97. Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, Leihman SF. MCV as a guide to phlebotomy therapy for hemochromatosis. Transfusion 2001;41:819-27.
98. Fleming RE, Holden CC, Tomatsu S, Waheed A, Brunt EM, Britton RS, Bacon BR, Roopenian DC, Sly WS. Mouse strain differences determine severity of iron accumulation in Hfe knockout model of hereditary hemochromatosis. Proc Natl Acad Sci U S A 2001;98:2707-11.
99. Dupic F, Fruchon S, Bensaid M, Barot N, Radosaljevic M, Loreal O, Brissot P, Gilfillan S, Bahram S, Coppin H, Roth M-P. Inactivation of the hemochromatosis gene differentially regulates duodenal expression of iron-related mRNAs between mouse strains. Gastroenterology 2002;122:745-51.
100. Bensaid M, Frucon S, Mazares C, Bahram S, Barot N, Coppin H, Roth M-P. A genome screen for modifier genes influencing iron accumulation in a murine model for hereditary hemochromatosis. Presented at Bioiron 2003, Bethesda, MD, USA, 2003 (poster).
101. Distante S, Berg JP, Lande K, Haug E, Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area or haemochromatosis. Gut 2000;47:575-9.
102. McCune CA, Al-Jader LN, May A, Hayes SL, Jackson HA, Worwood M. Hereditary haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002;111:538-43.
103. Cadet E, Capron D, Perez AS, Crépin SN, Arlot S, Ducroix J-P, Dautréaux M, Fardellone P, Leflon P, Merryweather-Clarke AT, Livesey KJ, Pointon JJ, Rose P, Harcourt J, Emery J, Sueur JM, Feyt R, Robson KJH, Rochelle J. A targetted approach significantly increases the identification rate of patients with undiagnosed haemochromatosis. J Intern Mod 2003;253:217-24.
104. Roest M, van der Schouw YT, de Valk B, Marx JJM, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosily for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-73.
105. Fuchs J, Podda M, Packer L, Kaufmann R. Morbidity risk in HFE associated hereditary hemochromatosis C282Y heterozygotes. Toxicology 2002;180(2):169-81.
106. Robson KJH, Lehmann DJ, Wimhurst VLC, Livesey KJ, Combrinck M, Merryweather-Clarke AT, Warden DR, Smith AD. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 2004;41:261-5.
107. Welch S, Langmead L. A comparison of the structure and properties of normal human transferrin and a genetic variant of human transferrin. Int J Biochem 1990;22:275-82.
108. Zhou B, Westaway SK, Levinson B, Johnson MA, Gitschier J, Hayflick SJ. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Sparz syndrome. Nat Genet 2001;28:345-9.
109. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-75.
110. Gorell JM, Ordidge RJ, Brown GG, Deniau JC, Buderer NM, Helpern JA. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology 1995,45:1138-43.
111. Curtis AR, Fey C, Morris CM, Bindoff LA, Ince PG, Chinnery PF, Coulthard A, Jackson MJ, Jackson AP, McHale DP, Hay D, Barker WA, Markham AF, Bates D, Curtis A, Burn J. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet 2001;28:350-4.
112. Ke Y, Qian ZM. Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003;2:246-53.
113. Merryweather-Clarke AT, Cadet E, Bamford A, Capron D, Viprakasit V, Miller A, McHugh PJ, Chapman RW, Pointon JJ, Wimhurst VLC, Livesey KJ, Tanphaichitr V, Rochette J, Robson KJ. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet 2003;12:2241-7
114. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increase the phenotypic expression HFE p.C282Y homozygous genatype. Blood 2004;103:2835-40.
115. Nicolas G, Andrews NC, Kahn A, Vaulont S. Hepcidin, a candidate modifier of the hemochromatosis phenotype in mice. Blood 2003;103:2841-3.
116. Crawford DH, Powell LW, Leggett BA, Francis JS, Fletcher LM, Webb SI, Halliday JW, Jaswinska EC. Evidence that the ancestral haplotype in Australian hemachromayosis patients may be associated with a common mutation in the gene. Am J Hum Genet 1995;57:362-7.
117. Piperno A, Arosio C, Fargion S, Roetto A, Nicoli C, Girelli D, Sbaiz L, Gasparini P, Boari G, Sampietro M, Camaschella C. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology 1996;24:43-6.
118. Piperno A, Sampietro M, Pietrangelo A, Arosio A, Lupica L, Montosi G, Vergani A, Fraquelli M, Girelli D, Pasquero P, Roetto A, Gasparini P, Fargion S, Conte D, Camaschella C. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998;114:994-1002.
119. Distante S, Robson KJ, Graham-Campbell J, Arnaiz-Villena A, Brissot P, Woorwood M. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet 2004, in press.
120. Fargion S, Valenti L, Dongiovanni P, Scaccabarozzi A, Fracanzani AL, Taioli E, Mattioli M, Sampietro M, Fiorelli G. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001;97:3707-12.
121. Cardosa CS, de Sousa M. HFE, the MHC and hemochromatosis: paradigm for an extended function for MHC class I. Tissue Antigens 2003;61:263-75.
122. Livesey KJ, Wimhurst VL, Carter K, Worwood M, Cadet E, Rochette J, Roberts AG, Pointon JJ, Merryweather-Clarke AT, Bassett ML, Jouanolle AM, Mosser A, David V, Poulton J, Robson KJ. The 16189 variant of mitochondrial DNA occurs more frequently in C282Y homozygotes with haemochromatosis than those without iron loading. J Med Genet 2004;41:6-10.
123. Hershko C, Peto TE, Weatherall DJ. Iron and infection. Br Med J (Clin Res Ed) 1988;296:660-4.
124. Marx JJ. Iron and infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002;15:411-26.
125. Krouse A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480:147-50.
126. Laftah AH, Ramesh B, Simpson RJ, Solanky N, Bahram S, Schumann K, Debnam ES, Srai SK. Effect of hepcidin on intestinal iron absorption in mice. Blood 2004;103:3940-4.
127. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-0.
128. Lee G. The anemia of chronic disease. Semin Haematol 1983;20:61-80.
129. Means RT Jr. The anaemia of infection. Bailliere's Best Pract Res Clin Haemotol 2000;13:151-62.
130. Roy CN, Custodio AO, de Graaf J, Schneider S, Akpan I, Montross LK, Sanchez M, Gaudino A, Hentze MW, Andrews NC, Muckenthaler MU. An Hfe-dependent pathway mediates hyposideremia in response to lipopolysaccharide-induced inflammation in mice. Nat Genet 2004;36:481-5.
131. Lebron JA, Bennett MJ, Vaughn DE, Chirino JA, Snow PM, Mintier GA, Feder JN, Bjorkman PJ. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with the transferrin receptor. Cell 1998;93:111-23.
132. 2-microglobulin-deficient mice. Immunol Lett 1994;39:105-11.
133. Levy JE, Montross LK, Andrewes NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000;105:1209-16.
134. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc Natl Acad Sci USA 1998;95:1148-53.
135. Gruenheid S, Cellier M, Vidal S, Gros P. Identification and characterization of a second mouse Nramp gene. Genomics 1995;25:514-25.
136. Cellier M, Govoni G, Vidal S, Kwan T, Groulx N, Liu J, Sanchez F, Skamene E, Schurr E, Gros P. Human natural resistance-associated macrophage protein: cDNA cloning, chromosomal mapping, genomic organization, and tissue-specific expression. J Exp Med 1994;180:1741-52.
137. Cellier M, Shustik C, Dalton W, Rich E, Hu J, Malo D, Schurr E, Gros P. Expression of the human NRAMP1 gene in professional primary phagocytes: studies in blood cells and in HL-60 promyelocytic leukemia. J Leuk Biol 1997;61:96-105.
138. Skamene E, Forget A. Genetic basis of host resistance and susceptibility ta intracellular pathogens. Adv Exp Med Biol 1988;239:23-37.
139. Jabado N, Jankowski A, Dougaparsad S, Picard V, Grinstein S, Gros P. Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. J Exp Med 2000;192:1237-48.
140. Hackam DJ, Rotstein OD, Zhang W, Gruenheid S, Gros P, Grinstein S. Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidification. J Exp Med 1998;188:351-64.
141. Gruenheid S, Cannone-Hergaux F, Gauthier S, Hackam DJ, Grinstein S, Gros P. The iron transport protein NRAMP2 is an integral membrane glycoprotein that colocalizes with transferrin in recycling endosomes. J Exp Med 1999;189:831-41.
142. de Souso M, Porto G. The immunological system in hemochromatosis. J Hepatol 1998;28:1-7.
143. Porto G, Vicente C, Teixeira MA, Martins O, Cabeda JM, Lacerda R, Goncalves C, Fraga J, Macedo G, Silva BM, Alves H, Justica B, de Sousa M. Relative impact of HLA phenotype and CD4-CD8 ratios on the clinical expression of hemochromatosis. Hepatology 1997;25:397-402.
144. Reimão R, Porto G, de Sousa M. Stability of CD4/CD8 ratios in man: new correlation between CD4/CD8 profiles and iron overload in idiopathic haemochromatosis patients. C R Acad Sci III 1991;313:481-7.
145. Cardosa C, Porto G, Lacerda R, Resende D, Rodrigues P, Bravo F, Oliveira JC, Justica B, de Sousa M. T-cell receptor repertoire in hereditary hemochromatosis: a study of 32 hemochromatosis patients and 274 healthy subjects. Hum Immunol 2001;62:488-99.
146. Xiong S, She H, Takeuchi H, Han B, Engelhardt JF, Barton CH, Zandi E, Giulivi C, Tsukamoto H. Signaling role of intracellular iron in NF-kappaB activation. J Biol Chem 2003;278:17646-54.
147. Boismenu R, Havran WL. Modulation of epithelial cell growth by ihtraepithelial gamma delta T cells. Science 1994;266:1253-5.
148. Kwak EL, Larochelle DA, Beaumont C, Torti SV, Torti FM. Role for NF-kappa B in the regulation of ferritin H by tumor necrosis foctar-alpha. J Biol Chem 1995;270:15285-93.
149. Sanchez C, Domenech N, Vazquez J, Alonso F, Ezquerra A, Dominguez J. The porcine 2A10 antigen is homologous to human CD163 and related to macrophage differentiation. J Immunol 1999;162:5230-7.
150. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
151. Schaer DJ, Boretti FS, Schoedon G, Schaffner A. Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel antiinflammatory action of glucocorticoids. Br J Haematol 2002;119:239-43.
152. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201.
153. Schaer DJ. The macrophage hemoglobin scavenger receptor (CD163) as a genetically determined disease modifying pathway in atherosclerosis. Atherosclerosis 2002;163(1):199-201.
154. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ. Regulation of reticuloendothelial iron transporter MTP1 (SIc11a3) by inflammation. J Biol Chem 2002;277:39786-91.
155. Yeh KY, Yen M, Glass J. Hepcidin regulation of ferroportin 1 expression in the liver and intestine of the rat. Am J Physiol Gastrointest Liver Physiol 2004;2:G385-94.
156. Henz S, Reichen J, Liechti-Gallati S. HLA-H gene mutations and haemochromatosis: the likely association of H63D with mild phenotype and the detection of S65C, a novel variant in exon 2. J Hepatol 1997;26(suppl 1):57.
157. Beutler E, Griffin MJ, Gelbart T, West C. A previously undescribed nonsense mutation of the HFE gene. Clin Genet 2002;61:40-2.
158. de Villiers JNP, Hillermann R, Loubser L, Kotze MJ. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. Hum Mol Genet 1999;8:1517-22.
159. Worwood M, Jackson HA, Feeney GP, Edwards C, Bower, DJ. A single tube heteroduplex PCR for the common HFE genotypes. Blood 1999;94:405a.
160. Liechti-Gallati S, Schneider V, Neeser D, Kraemer R. Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease. Eur J Hum Genet 1999;7:590-8.
161. Barton JC, Sawada-hirai R, Rothenberg BE, Acton RT. Two novel missense mutations in the HFE gene (I105T and G93R) and identification of the S65C mutation in Alabama hemochromatosis probands. Blood Cell Mol Dis 1999;25:146-54.
162. Oberkanins C, Moritz A, de Villiers JN, Kotze MJ, Kury F. A reverse-hybridization assay for the rapid and simultaneous detection of nine HFE gene mutations. Genet Test 2000;4:121-4.
163. Piperno A, Arosio C, Fossati L, Vigano M, Trombini P, Vergani A, Mancia G. Two novel nonsense mutations of HFE gene in five unrelated Italian patients with hemochromatosis. Gastroenterology 2000;119:441-5.
164. Bradbury R, Fagan E, Payne SJ. Two novel polymorphisms (E277K and V212V) in the haemochromatosis gene HFE. Hum Mutat 2000;15:120.
165. Rosmorduc O, Poupon O, Nion I, Wendum D, Feder J, Béréziat G, Hermelin B. Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology 2000;119:1075-86.
166. Imanishi H, Liu W, Cheng J, Ikeda N, Amuro Y, Hada T. Idiopathic hemochromatosis with the mutation of Ala176Val heterozygous For HFE gene. Intern Med 2001;40:479-83.
167. Jones DC, Young NT, Pigott C, Fuggle SV, Barnardo MC, Marshall SE, Bunce M. Comprehensive hereditary hemochromatosis genotyping. Tissue Antigens 2002;60:481-8.
168. Le Gac GG, Dupradeau FY, Mura C, Jacalot S, Scotet V, Esnault G, Mercier AY, Rochette J, Ferec C. Phenotypic expression of the C282Y/Q283P compound heterozygosity in HFE and molecular modeling of the Q283P mutation effect. Blood Cell Mol Dis 2003;30:231-7.
169. Kinkely SM, Brown BD, Lyng AT, Harrison WK, Schep GN, Goddard-Hill AC, Aubrey ME, Lillicrap D, Taylor SA. Absence or overt iron overload in two individuals compound heterozygotes for a 22 base poir deletion of exon 2 and the C282Y missense mutation of the HFE gene. Clin Genet 2003;63:163-5.
170. De Gabbi M, Daraio F, Oberkanins C, Moritz A, Kury F, Fiorelli G, Camaschella C. Analysis of HFE and TFR2 mutations in selected blood donors with biochemical parameters of iron overload. Haematologica 2003;88:396-401.
171. Wallace DF, Dooley JS, Walker AP. A novel mutation of HFE explains the classical phenotype of genetic haemochromatosis in a C282Y heterozygote. Gastroenterology 1999;116:1409-12.
172. Wigg AJ, Harley H, Casey G. Heterozygous recipient and donor HFE mutations associated with a hereditary haemochromatosis phenotype after liver transplantation. Gut 2003;52:433-5.
173. 2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci U S A 1997;94:12384-9.
174. Ramolingam TS, West Jr AP, Lebrón JA, Nangiana JS, Hogan TH, Enns CA, Bjorkman PJ. Binding of the transferrin receptor is required for endocytosis of HFE and regulation of iron homeostasis. Nat Cell Biol 2000;2:953-7.
175. Wallace DF, Clark RM, Harley HA, Subromaniam VN. Autasomal dominant iron overload due to a novel mutation of ferroportin 1 associated with porenchymal iron loading and cirrhosis. J Hepatol 2004;40:710-3.